LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

13.37 3.16

Overview

Share price change

24h

Current

Min

13.19

Max

13.41

Key metrics

By Trading Economics

Income

-6.9M

6M

Sales

9.4M

162M

P/E

Sector Avg

69.6

56.602

Profit margin

3.676

Employees

1,811

EBITDA

5.6M

-5M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+59.28% upside

Market Stats

By TradingEconomics

Market Cap

-183M

2.5B

Previous open

10.21

Previous close

13.37

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 maj 2025, 19:39 UTC

Major Market Movers

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 maj 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 maj 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16 maj 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 maj 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 maj 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 maj 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 maj 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 maj 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 maj 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 maj 2025, 20:55 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 maj 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 maj 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 maj 2025, 20:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 maj 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 maj 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 maj 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 maj 2025, 20:15 UTC

Earnings

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 maj 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: William K. Daniel Joins Board

16 maj 2025, 20:10 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 maj 2025, 20:05 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 maj 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 maj 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 maj 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 maj 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 maj 2025, 18:32 UTC

Top News

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 maj 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

59.28% upside

12 Months Forecast

Average 20.85 USD  59.28%

High 27 USD

Low 14.7 USD

Based on 2 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.